Skip to main content
Premium Trial:

Request an Annual Quote

Patricia Scheller New CEO of SomaLogic; Baird Venture Partners Add Staff; John Delyani New Quark VP; and Others

NEW YORK, Aug. 13 (GenomeWeb News) - Patricia Scheller has been appointed CEO of SomaLogic, the privately-held proteomics company said Aug. 12.

 

Scheller comes to SomaLogic, of Boulder, Colo., from Ortho-Clinical Diagnostics, a division of Johnson & Johnson, where she managed the global business unit and the global donor screening unit, according to SomaLogic. Prior to this, Scheller was vice president of marketing and vice president of chemistry at Dade Behring, as well as director of cardiology systems at Cordis, another Johnson & Johnson company.

 

Scheller will additionally join SomaLogic's board of directors.


 

James Daverman, Wei Li, James Pavlik, and H. Josef Merrill have joined Baird Venture Partners, of Milwaukee, Wis., the firm said Aug. 12.

 

Daverman will serve as senior advisor and chairman of the company's advisory board; Li and Pavlik will be associates; and Merrill is joining the company as a financial analyst.

 

Daverman is a co-founder and managing partner of Marquette Venture Partners, and is a 20-year veteran of the venture capital sector, the firm said. He is a director of CollaGenex Pharmaceuticals and Welch Allyn Holdings, in addition to several private companies.

 

Li, who will work in the life sciences area, comes to BVP from Vertex Pharmaceuticals, where he was involved in drug discovery and technology licensing. He previously held a marketing position at Serono, based in Geneva.

 

Pavlik, who will work in technology, previously held a position at Madison Dearborn Partners in communications investments, and at Salomon Smith Barney, contributing to equity and fixed income financings and mergers and acquisitions.

 

Merrill transfers to BVP from Robert W. Baird's investment banking group, where he was an analyst.

 

Baird Venture Partners said Aug. 12 it had  just closed on the second round of a $90 million regional investment fund and has investments in microarray firm NimbleGen.


 

John Delyani has been appointed vice president of business development at Quark Biotech, the company said Aug. 12.

 

Delyani, who will work from the recently-opened Fremont, Calif. facility, comes to Quark from Pharmacia, where he was director of technology acquisition and operations, and previously, associate director of cardiovascular and metabolic diseases.


 

Richard Gibbs, Jorge Galan, and W. Ian Lipkin have all been named to the scientific advisory board of 454 Life Sciences, the majority-owned subsidiary of Curagen, 454 said Aug. 11.

 

Gibbs is director of Baylor's human genome sequencing center and a professor of molecular and human genetics at Baylor College of Medicine; Galan is professor and chairman of microbial pathogenesis at Yale School of Medicine; and Lipkin is a professor of epidemiology and director of the infectious disease laboratory at Columbia University's Mailman School of Public Health, as well as a professor of pathology and neurology at Columbia University College of Physicians and Surgeons.

 

These advisors' "insights will be invaluable to us as 454 Life Sciences plans for the commercialization of its technology to initially sequence whole viral and bacterial genomes to address some of the most urgent needs in drug discovery, biodefense, and the growing threat of emerging pathogens," Richard Begley, president and CEO of the Branford, Conn., company, said in a statement.

 

 

 

 

 

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.